Botulinum toxin: chemistry, pharmacology, toxicity, and immunology
MF Brin - Muscle & Nerve: Official Journal of the American …, 1997 - Wiley Online Library
The seven serotypes of botulinum toxin (BTX) produced by Clostridium botulinum exert their
paralytic effect by inhabiting acetylcholine release at the neuromuscular junction. Each of …
paralytic effect by inhabiting acetylcholine release at the neuromuscular junction. Each of …
Immunogenicity of botulinum toxins
M Naumann, LM Boo, AH Ackerman… - Journal of neural …, 2013 - Springer
Botulinum neurotoxins are formulated biologic pharmaceuticals used therapeutically to treat
a wide variety of chronic conditions, with varying governmental approvals by country. Some …
a wide variety of chronic conditions, with varying governmental approvals by country. Some …
Botulinum toxin A for axillary hyperhidrosis (excessive sweating)
M Heckmann, AO Ceballos-Baumann… - New England Journal …, 2001 - Mass Medical Soc
Background Treatment of primary focal hyperhidrosis is often unsatisfactory. Botulinum toxin
A can stop excessive sweating by blocking the release of acetylcholine, which mediates …
A can stop excessive sweating by blocking the release of acetylcholine, which mediates …
Response and immunoresistance to botulinum toxin injections
J Jankovic, K Schwartz - Neurology, 1995 - AAN Enterprises
Botulinum toxin antibodies (ABS) may be a reason why occasionally patients do not have a
response to injections with botulinum toxin type A (BTX). We tested 86 patients with cervical …
response to injections with botulinum toxin type A (BTX). We tested 86 patients with cervical …
Botulinum-A toxin as a treatment of detruosor-sphincter dyssynergia: a prospective study in 24 spinal cord injury patients
B Schurch, D Hauri, B Rodic, A Curt, M Meyer… - The Journal of …, 1996 - auajournals.org
Purpose: The paralytic effect of botulinum-A toxin injections on the external urethral
sphincter was investigated prospectively in patients with neurogenic voiding disorders …
sphincter was investigated prospectively in patients with neurogenic voiding disorders …
Botulinum toxin therapy, immunologic resistance, and problems with available materials
G Borodic, E Johnson, M Goodnough, E Schantz - Neurology, 1996 - AAN Enterprises
Botulinum toxin injections have become an extremely useful therapeutic modality in the
treatment of certain segmental movement disorders such as blepharospasm, adult onset …
treatment of certain segmental movement disorders such as blepharospasm, adult onset …
Positive effects of extracorporeal shock wave therapy on spasticity in poststroke patients: a meta-analysis
P Guo, F Gao, T Zhao, W Sun, B Wang, Z Li - Journal of Stroke and …, 2017 - Elsevier
Background Spasticity is a common and serious complication following a stroke, and many
clinical research have been conducted to evaluate the effect of extracorporeal shock wave …
clinical research have been conducted to evaluate the effect of extracorporeal shock wave …
Botulinum toxin A treatment in facial palsy synkinesis: a systematic review and meta-analysis
FW de Jongh, AWMA Schaeffers, ZE Kooreman… - European archives of …, 2023 - Springer
Background Synkinesis is defined as involuntary movements accompanying by voluntary
movements and can occur during the aftermath of peripheral facial palsy, causing functional …
movements and can occur during the aftermath of peripheral facial palsy, causing functional …
The beneficial antispasticity effect of botulinum toxin type A is maintained after repeated treatment cycles
AMO Bakheit, NV Fedorova, AA Skoromets… - Journal of Neurology …, 2004 - jnnp.bmj.com
Objective: To study the efficacy, safety, and incidence of BtxA antibody formation with
repeated treatments with BtxA in post-stroke upper limb muscle spasticity. Methods: The …
repeated treatments with BtxA in post-stroke upper limb muscle spasticity. Methods: The …
Pharmacologic characterization of botulinum toxin for basic science and medicine
LB Pearce, ER First, RD Maccallum, A Gupta - Toxicon, 1997 - Elsevier
The use of Botulinum neurotoxin (BoNT) is increasing in both clinical and basic science.
Clinically, intramuscular injection of nanogram quantities of BoNT is fast becoming the …
Clinically, intramuscular injection of nanogram quantities of BoNT is fast becoming the …